GlassScriptPhysician profile
Stephen R Cannon
NPI 1083777908
$1,847.34
in general payments reported to CMS, 2019-2025
31 companies · $595 in 2025
The $595 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $131 · 2021: $11.77 · 2022: $52.75 · 2023: $124 · 2024: $275 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $994.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $330.37 | 2022-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $317.71 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $125.35 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $117.11 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $92.27 | 2019 | |
| Merck Sharp & Dohme LLC | $80.51 | 2019 | |
| Pfizer INC. | $76.65 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.96 | 2025 | Caplyta |
| Amgen INC. | $55.20 | 2019-2023 | Prolia, Evenity |
| Sanofi-Aventis U.S. LLC | $51.71 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $49.69 | 2020-2025 | Contrave |
| Ironwood Pharmaceuticals, INC | $49.52 | 2019-2022 | |
| Ardelyx, INC. | $48.32 | 2024-2025 | Ibsrela |
| Teva Pharmaceuticals USA, INC. | $36.66 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.84 | 2019-2024 | Jardiance |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.72 | 2025 | Xifaxan, Trulance, Relistor |
| Phathom Pharmaceuticals, INC. | $31.54 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $26.53 | 2019-2020 | |
| Boston Scientific Corporation | $25.60 | 2025 | Watchman Flx |
| Ironshore Pharmaceuticals INC. | $24.21 | 2019 | |
| Edwards Lifesciences Corporation | $21.36 | 2024 | |
| Astellas Pharma US INC | $20.82 | 2019 | |
| Exact Sciences Corporation | $19.21 | 2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $18.46 | 2023 | Qelbree |
| Nevro Corp. | $16.97 | 2019 | |
| Adlon Therapeutics L.P. | $16.00 | 2019 | |
| Medtronic, INC. | $14.60 | 2023 | Interstim |
| Corvista Health, INC. | $13.55 | 2025 | Corvista System |
| Amarin Pharma, INC. | $12.84 | 2019 | |
| Shire North American Group INC | $12.07 | 2019 | |
| Novartis Pharmaceuticals Corporation | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Cannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.